vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and ZIPRECRUITER, INC. (ZIP). Click either name above to swap in a different company.
ZIPRECRUITER, INC. is the larger business by last-quarter revenue ($111.7M vs $86.8M, roughly 1.3× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 0.6%). ZIPRECRUITER, INC. produced more free cash flow last quarter ($7.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -4.4%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ZipRecruiter, Inc. is an American employment marketplace for job seekers and employers.
IOVA vs ZIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $111.7M |
| Net Profit | — | $-835.0K |
| Gross Margin | 67.4% | 89.1% |
| Operating Margin | -84.7% | 3.6% |
| Net Margin | — | -0.7% |
| Revenue YoY | 17.7% | 0.6% |
| Net Profit YoY | — | 92.3% |
| EPS (diluted) | — | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $111.7M | ||
| Q3 25 | $67.5M | $115.0M | ||
| Q2 25 | $60.0M | $112.2M | ||
| Q1 25 | $49.3M | $110.1M | ||
| Q4 24 | $73.7M | $111.0M | ||
| Q3 24 | $58.6M | $117.1M | ||
| Q2 24 | $31.1M | $123.7M | ||
| Q1 24 | $715.0K | $122.2M |
| Q4 25 | — | $-835.0K | ||
| Q3 25 | $-91.3M | $-9.8M | ||
| Q2 25 | $-111.7M | $-9.5M | ||
| Q1 25 | $-116.2M | $-12.8M | ||
| Q4 24 | — | $-10.8M | ||
| Q3 24 | $-83.5M | $-2.6M | ||
| Q2 24 | $-97.1M | $7.0M | ||
| Q1 24 | $-113.0M | $-6.5M |
| Q4 25 | 67.4% | 89.1% | ||
| Q3 25 | 43.0% | 89.1% | ||
| Q2 25 | 5.5% | 89.3% | ||
| Q1 25 | -0.8% | 89.4% | ||
| Q4 24 | 68.7% | 89.6% | ||
| Q3 24 | 46.2% | 89.4% | ||
| Q2 24 | -0.8% | 89.5% | ||
| Q1 24 | — | 89.1% |
| Q4 25 | -84.7% | 3.6% | ||
| Q3 25 | -140.7% | -4.4% | ||
| Q2 25 | -189.8% | -5.9% | ||
| Q1 25 | -245.8% | -10.6% | ||
| Q4 24 | -117.5% | -3.6% | ||
| Q3 24 | -152.1% | -2.8% | ||
| Q2 24 | -327.6% | 7.6% | ||
| Q1 24 | -16464.6% | -0.7% |
| Q4 25 | — | -0.7% | ||
| Q3 25 | -135.3% | -8.5% | ||
| Q2 25 | -186.2% | -8.5% | ||
| Q1 25 | -235.5% | -11.7% | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | -142.7% | -2.2% | ||
| Q2 24 | -312.2% | 5.7% | ||
| Q1 24 | -15800.8% | -5.3% |
| Q4 25 | — | $-0.03 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | $-0.33 | $-0.10 | ||
| Q1 25 | $-0.36 | $-0.13 | ||
| Q4 24 | $-0.24 | $-0.10 | ||
| Q3 24 | $-0.28 | $-0.03 | ||
| Q2 24 | $-0.34 | $0.07 | ||
| Q1 24 | $-0.42 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $188.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $-77.2M |
| Total Assets | $913.2M | $569.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $188.0M | ||
| Q3 25 | $300.8M | $211.8M | ||
| Q2 25 | $301.2M | $203.5M | ||
| Q1 25 | $359.7M | $221.1M | ||
| Q4 24 | $323.8M | $218.4M | ||
| Q3 24 | $397.5M | $225.6M | ||
| Q2 24 | $412.5M | $271.7M | ||
| Q1 24 | $356.2M | $282.5M |
| Q4 25 | $698.6M | $-77.2M | ||
| Q3 25 | $702.3M | $-76.1M | ||
| Q2 25 | $698.5M | $-65.9M | ||
| Q1 25 | $767.9M | $-11.3M | ||
| Q4 24 | $710.4M | $13.4M | ||
| Q3 24 | $773.5M | $13.6M | ||
| Q2 24 | $768.5M | $24.4M | ||
| Q1 24 | $680.0M | $12.7M |
| Q4 25 | $913.2M | $569.7M | ||
| Q3 25 | $904.9M | $573.6M | ||
| Q2 25 | $907.4M | $592.4M | ||
| Q1 25 | $966.7M | $629.4M | ||
| Q4 24 | $910.4M | $664.1M | ||
| Q3 24 | $991.1M | $652.0M | ||
| Q2 24 | $964.3M | $665.3M | ||
| Q1 24 | $869.8M | $662.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $7.7M |
| Free Cash FlowOCF − Capex | $-61.9M | $7.6M |
| FCF MarginFCF / Revenue | -71.3% | 6.8% |
| Capex IntensityCapex / Revenue | 10.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $7.7M | ||
| Q3 25 | $-78.7M | $2.6M | ||
| Q2 25 | $-67.4M | $10.5M | ||
| Q1 25 | $-103.7M | $-9.9M | ||
| Q4 24 | $-73.3M | $12.5M | ||
| Q3 24 | $-59.0M | $9.3M | ||
| Q2 24 | $-98.4M | $21.9M | ||
| Q1 24 | $-122.3M | $2.0M |
| Q4 25 | $-61.9M | $7.6M | ||
| Q3 25 | $-89.5M | $2.2M | ||
| Q2 25 | $-74.9M | $10.2M | ||
| Q1 25 | $-109.9M | $-10.2M | ||
| Q4 24 | $-77.5M | $12.0M | ||
| Q3 24 | $-61.3M | $9.2M | ||
| Q2 24 | $-98.9M | $21.7M | ||
| Q1 24 | $-126.5M | $1.9M |
| Q4 25 | -71.3% | 6.8% | ||
| Q3 25 | -132.7% | 1.9% | ||
| Q2 25 | -124.9% | 9.1% | ||
| Q1 25 | -222.8% | -9.3% | ||
| Q4 24 | -105.1% | 10.8% | ||
| Q3 24 | -104.6% | 7.8% | ||
| Q2 24 | -317.9% | 17.6% | ||
| Q1 24 | -17685.3% | 1.6% |
| Q4 25 | 10.7% | 0.1% | ||
| Q3 25 | 16.1% | 0.3% | ||
| Q2 25 | 12.4% | 0.3% | ||
| Q1 25 | 12.6% | 0.3% | ||
| Q4 24 | 5.7% | 0.4% | ||
| Q3 24 | 3.9% | 0.2% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 583.4% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.12× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
ZIP
| License | $84.3M | 75% |
| Services | $27.4M | 25% |
